AiCure’s phone app helps clinical trials keep tabs on which participants have taken their medications correctly and which have not.
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Diversity of Women Veterans’ Experiences Myths vs Reality In this paper, we tackle one of the most common myths about VA healthcare. At Ipsos Public Affairs, we […]
Cellectis announced a paper published in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors and cause a micro secretion of therapeutic proteins onto these tumors, which ultimately reshapes the tumor microenvironment and improves the T-cells ability to fight cancer.
The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.
Renaissance genius Leonardo da Vinci’s litany of exquisite but unfinished work shows he probably had an attention disorder common to modern society.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
